Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$2.25 - $5.8 $33,750 - $87,000
-15,000 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$2.22 - $3.39 $4,440 - $6,780
2,000 Added 15.38%
15,000 $1,000
Q2 2019

Aug 13, 2019

BUY
$1.8 - $3.3 $23,400 - $42,900
13,000 New
13,000 $10,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.